<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01351805</url>
  </required_header>
  <id_info>
    <org_study_id>R01AR059086</org_study_id>
    <secondary_id>R01AR059086</secondary_id>
    <nct_id>NCT01351805</nct_id>
  </id_info>
  <brief_title>Vitamin D and Fish Oil for Autoimmune Disease, Inflammation and Knee Pain</brief_title>
  <acronym>VITAL</acronym>
  <official_title>Vitamin D and Fish Oil for Autoimmune Disease, Inflammation and Knee Pain</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Brigham and Women's Hospital</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>National Institute of Arthritis and Musculoskeletal and Skin Diseases (NIAMS)</agency>
      <agency_class>NIH</agency_class>
    </collaborator>
  </sponsors>
  <source>Brigham and Women's Hospital</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The VITamin D and OmegA-3 TriaL (VITAL; NCT 01169259) is a randomized clinical trial in&#xD;
      25,871 U.S. men and women investigating whether taking daily dietary supplements of vitamin&#xD;
      D3 (2000 IU) or omega-3 fatty acids (OmacorÂ® fish oil, 1 gram) reduces the risk of developing&#xD;
      cancer, heart disease, and stroke in people who do not have a prior history of these&#xD;
      illnesses. This ancillary study is being conducted among VITAL participants and will examine&#xD;
      whether vitamin D or fish oil have effects upon A) autoimmune disease incidence, B)&#xD;
      biomarkers of systemic inflammation, and C) chronic knee pain. Blood samples at baseline and&#xD;
      in follow-up will be collected in a randomly selected subcohort of 1500 individuals and&#xD;
      analyzed for changes in biomarkers of systemic inflammation: C-reactive protein,&#xD;
      interleukin-6, and tumor necrosis factor-receptor 2. Approximately 1300 individuals with&#xD;
      chronic, frequent knee pain will be followed with annual questionnaires to evaluate the&#xD;
      effects of the supplements on chronic knee pain.&#xD;
    </textblock>
  </brief_summary>
  <overall_status>Active, not recruiting</overall_status>
  <start_date type="Actual">November 2011</start_date>
  <completion_date type="Anticipated">April 2022</completion_date>
  <primary_completion_date type="Anticipated">April 2022</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Factorial Assignment</intervention_model>
    <primary_purpose>Prevention</primary_purpose>
    <masking>Triple (Participant, Investigator, Outcomes Assessor)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Serum Levels of Biomarkers of Systemic Inflammation: Interleukin-6 (IL-6)</measure>
    <time_frame>Baseline and 1 year</time_frame>
    <description>In a subsample of the randomized trial population across the four arms, blood samples at baseline and in follow-up were collected and analyzed for changes in biomarkers of systemic inflammation: C-reactive protein (CRP), interleukin-6 (IL-6), and tumor necrosis factor-receptor 2 (TNFR2). We tested whether either or both supplements were associated with a decrease in the biomarkers of systemic inflammation (blood biomarker levels among those receiving supplements vs. placebo).</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Serum Levels of Biomarkers of Systemic Inflammation: C-reactive Protein (CRP)</measure>
    <time_frame>Baseline and 1 year</time_frame>
    <description>In a subsample of the randomized trial population across the four arms, blood samples at baseline and in follow-up were collected and analyzed for changes in biomarkers of systemic inflammation: C-reactive protein (CRP), interleukin-6 (IL-6), and tumor necrosis factor-receptor 2 (TNFR2). We tested whether either or both supplements were associated with a decrease in the biomarkers of systemic inflammation (blood biomarker levels among those receiving supplements vs. placebo).</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Serum Levels of Biomarkers of Systemic Inflammation: Tumor Necrosis Factor-receptor 2 (TNFR2)</measure>
    <time_frame>Baseline and 1 year</time_frame>
    <description>In a subsample of the randomized trial population across the four arms, blood samples at baseline and in follow-up were collected and analyzed for changes in biomarkers of systemic inflammation: C-reactive protein (CRP), interleukin-6 (IL-6), and tumor necrosis factor-receptor 2 (TNFR2). We tested whether either or both supplements were associated with a decrease in the biomarkers of systemic inflammation (blood biomarker levels among those receiving supplements vs. placebo).</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Incident Autoimmune Diseases</measure>
    <time_frame>5 years (Data are not yet published. They are under review at journal and embargoed.)</time_frame>
    <description>All participants will be followed for the development of new autoimmune diseases, including, but not limited to, rheumatoid arthritis, psoriasis, autoimmune thyroid disease, inflammatory bowel disease and polymyalgia rheumatica.&#xD;
Data are not yet published. They are under review at journal and embargoed.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Interactions Between the Effects of Vitamin D and Those of Fish Oils for Each of the Primary Outcomes. Reported With Main Results.</measure>
    <time_frame>5 years (Data are not yet published. They are under review at journal and embargoed.)</time_frame>
    <description>We will test for interactions between the effects of vitamin D and those of fish oils for each of the primary outcomes above: (A) whether either or both supplements are associated with reduced numbers of new cases of autoimmune diseases; (B) whether either or both supplements are associated with reductions in biomarkers of systemic inflammation and; (C) whether either or both supplements are associated with reduced levels of knee pain at the end of the trial.&#xD;
Data are not yet published. They are under review at journal and embargoed.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Subgroup Analysis of Primary Outcomes. Reported With Main Results, Primary Outcomes.</measure>
    <time_frame>5 years (Data are not yet published. They are under review at journal and embargoed.)</time_frame>
    <description>We will test for differential effects of and interactions between vitamin D and fish oils for each of the three primary outcomes, according to participant age, race, sex and BMI. We will test for these interactions for each of the primary aims above: (A) whether either or both supplements are associated with reduced numbers of new cases of autoimmune diseases; (B) whether either or both supplements are associated with reductions in biomarkers of systemic inflammation and; (C) whether either or both supplements are associated with reduced levels of knee pain at the end of the trial.&#xD;
Data are not yet published. They are under review at journal and embargoed.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Incident Autoimmune Disease</measure>
    <time_frame>8 years (Data are not yet published. They are under review at journal and embargoed.)</time_frame>
    <description>Development of new autoimmune diseases through open-label extension beyond the randomized 5 years&#xD;
Data are not yet published. They are under review at journal and embargoed.</description>
  </secondary_outcome>
  <other_outcome>
    <measure>Severity of Knee Pain in Subsample With Chronic, Frequent Knee Pain at Baseline- With n-3 FA</measure>
    <time_frame>Baseline and 5 years</time_frame>
    <description>Western Ontario and McMaster University Osteoarthritis Index (WOMAC) Pain was the primary outcome on a scale of 0-100 with 100= worst pain.&#xD;
Subsample of VITAL participants with chronic, frequent knee pain at trial baseline were followed with annual WOMAC questionnaires to test for change in severity of chronic knee pain in those taking Omega-3 fish oil (n-3 FA) supplements compared to those taking placebo. We tested whether n-3 FA supplements are associated with reduced levels of WOMAC knee pain at the end of the trial (comparing knee pain outcomes in those receiving supplements to placebo).</description>
  </other_outcome>
  <other_outcome>
    <measure>Severity of Knee Pain in Subsample With Chronic, Frequent Knee Pain at Baseline- With Vitamin D</measure>
    <time_frame>Baseline and 5 years</time_frame>
    <description>Western Ontario and McMaster University Osteoarthritis Index (WOMAC) Pain was the primary outcome on a scale of 0-100 with 100= worst pain.&#xD;
Subsample of VITAL participants with chronic, frequent knee pain at trial baseline were followed with annual WOMAC questionnaires to test for change in severity of chronic knee pain in those taking Vitamin D supplements compared to those taking placebo. We tested whether Vitamin D supplements were associated with reduced levels of WOMAC knee pain at the end of the trial (comparing knee pain outcomes in those receiving supplements to placebo).</description>
  </other_outcome>
  <number_of_arms>4</number_of_arms>
  <enrollment type="Actual">25871</enrollment>
  <condition>Autoimmune Diseases</condition>
  <condition>Systemic Inflammatory Process</condition>
  <condition>Knee Pain Chronic</condition>
  <condition>Osteoarthritis</condition>
  <condition>Rheumatoid Arthritis</condition>
  <arm_group>
    <arm_group_label>Fish Oil</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Subjects will receive marine omega-3 fatty acids (465 mg of eicosapentaenoic acid [EPA] and 375 mg of docosahexaenoic acid [DHA]).</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Vitamin D</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Subjects will receive vitamin D3 (cholecalciferol) 2000 IU a day.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>placebo</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>Subjects will receive placebo pill.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Vitamin D and Fish Oil</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Subjects will receive marine omega-3 fatty acids (465 mg of eicosapentaenoic acid [EPA] and 375 mg of docosahexaenoic acid [DHA]).</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Fish Oil</intervention_name>
    <description>Subjects will receive marine omega-3 fatty acids (465 mg of eicosapentaenoic acid [EPA] and 375 mg of docosahexaenoic acid [DHA]).</description>
    <arm_group_label>Fish Oil</arm_group_label>
    <arm_group_label>Vitamin D and Fish Oil</arm_group_label>
    <other_name>eicosapentaenoic acid (EPA)</other_name>
    <other_name>docosahexaenoic acid (DHA)</other_name>
    <other_name>marine fatty acids</other_name>
    <other_name>omega-3 fatty acids</other_name>
    <other_name>fish oils</other_name>
  </intervention>
  <intervention>
    <intervention_type>Dietary Supplement</intervention_type>
    <intervention_name>Vitamin D</intervention_name>
    <description>Subjects will receive vitamin D3 (cholecalciferol) 2000 IU a day.</description>
    <arm_group_label>Vitamin D</arm_group_label>
    <arm_group_label>Vitamin D and Fish Oil</arm_group_label>
    <other_name>cholecalciferol</other_name>
    <other_name>vitamin D3</other_name>
  </intervention>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>placebo pill</intervention_name>
    <description>placebo</description>
    <arm_group_label>Fish Oil</arm_group_label>
    <arm_group_label>Vitamin D</arm_group_label>
    <arm_group_label>placebo</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        As for the parent trial, VITamin D and OmegA-3 TriaL (VITAL; NCT 01169259). Individuals&#xD;
        with chronic, frequent knee pain at study baseline will be followed as a subcohort. Trial&#xD;
        enrollment complete.&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>50 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Karen H Costenbader, MD, MPH</last_name>
    <role>Principal Investigator</role>
    <affiliation>Brigham and Women's Hospital</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Brigham and Women's Hospital</name>
      <address>
        <city>Boston</city>
        <state>Massachusetts</state>
        <zip>02115</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <link>
    <url>http://www.vitalstudy.org/</url>
    <description>Welcome to the VITAL Study Website</description>
  </link>
  <results_reference>
    <citation>Costenbader KH, MacFarlane LA, Lee IM, Buring JE, Mora S, Bubes V, Kotler G, Camargo CA Jr, Manson JE, Cook NR. Effects of One Year of Vitamin D and Marine Omega-3 Fatty Acid Supplementation on Biomarkers of Systemic Inflammation in Older US Adults. Clin Chem. 2019 Dec;65(12):1508-1521. doi: 10.1373/clinchem.2019.306902. Epub 2019 Nov 7.</citation>
    <PMID>31699704</PMID>
  </results_reference>
  <results_reference>
    <citation>MacFarlane LA, Cook NR, Kim E, Lee IM, Iversen MD, Gordon D, Buring JE, Katz JN, Manson JE, Costenbader KH. The Effects of Vitamin D and Marine Omega-3 Fatty Acid Supplementation on Chronic Knee Pain in Older US Adults: Results From a Randomized Trial. Arthritis Rheumatol. 2020 Nov;72(11):1836-1844. doi: 10.1002/art.41416. Epub 2020 Oct 3.</citation>
    <PMID>32583982</PMID>
  </results_reference>
  <verification_date>March 2021</verification_date>
  <study_first_submitted>May 4, 2011</study_first_submitted>
  <study_first_submitted_qc>May 10, 2011</study_first_submitted_qc>
  <study_first_posted type="Estimate">May 11, 2011</study_first_posted>
  <results_first_submitted>October 8, 2020</results_first_submitted>
  <results_first_submitted_qc>December 10, 2020</results_first_submitted_qc>
  <results_first_posted type="Actual">January 8, 2021</results_first_posted>
  <last_update_submitted>March 15, 2021</last_update_submitted>
  <last_update_submitted_qc>March 15, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">April 12, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Brigham and Women's Hospital</investigator_affiliation>
    <investigator_full_name>Karen H. Costenbader</investigator_full_name>
    <investigator_title>Associate Physician</investigator_title>
  </responsible_party>
  <keyword>vitamin D</keyword>
  <keyword>omega-3 fatty acid</keyword>
  <keyword>fish oil</keyword>
  <keyword>prevention</keyword>
  <keyword>trial</keyword>
  <keyword>autoimmune disease</keyword>
  <keyword>rheumatoid arthritis</keyword>
  <keyword>psoriasis</keyword>
  <keyword>systemic inflammation</keyword>
  <keyword>Interleukin-6</keyword>
  <keyword>C-reactive peptide</keyword>
  <keyword>tumor necrosis factor</keyword>
  <keyword>osteoarthritis</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Arthritis</mesh_term>
    <mesh_term>Osteoarthritis</mesh_term>
    <mesh_term>Arthritis, Rheumatoid</mesh_term>
    <mesh_term>Autoimmune Diseases</mesh_term>
    <mesh_term>Inflammation</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Vitamin D</mesh_term>
    <mesh_term>Ergocalciferols</mesh_term>
    <mesh_term>Cholecalciferol</mesh_term>
    <mesh_term>Vitamins</mesh_term>
  </intervention_browse>
  <provided_document_section>
    <provided_document>
      <document_type>Study Protocol and Statistical Analysis Plan</document_type>
      <document_has_protocol>Yes</document_has_protocol>
      <document_has_icf>No</document_has_icf>
      <document_has_sap>Yes</document_has_sap>
      <document_date>November 9, 2009</document_date>
      <document_url>https://ClinicalTrials.gov/ProvidedDocs/05/NCT01351805/Prot_SAP_000.pdf</document_url>
    </provided_document>
  </provided_document_section>

  <clinical_results>

    <participant_flow>
      <recruitment_details>From the 25871 VITAL participants, we identified 2 main subcohorts: A &quot;systemic inflammation&quot; subcohort of 1561 participants with sufficient blood biomarker assays, balanced by sex, and matched on blood draw season, and a second &quot;knee pain&quot; subcohort including 1,398 participants who returned one knee pain questionnaire and qualified at baseline.</recruitment_details>
      <pre_assignment_details>At 1 year, 95% of participants returned follow-up questionnaires, and approximately 90% were taking more than two-thirds of study pills (definition of compliance).&#xD;
Participants willing to provide a blood sample were sent a kit with consent form, supplies, and instructions to have blood drawn.</pre_assignment_details>
      <group_list>
        <group group_id="P1">
          <title>ACTIVE Vitamin D + ACTIVE Omega-3 Fatty Acids</title>
          <description>ACTIVE Vitamin D = Vitamin D3, one 2000 IU capsule/day; ACTIVE Omega-3 Fatty Acids = Omacor, one 1-gram capsule/day. Each capsule of Omacor contains 840 milligrams of marine omega-3 fatty acids (465 mg of eicosapentaenoic acid [EPA] and 375 mg of docosahexaenoic acid [DHA]).</description>
        </group>
        <group group_id="P2">
          <title>ACTIVE Vitamin D + PLACEBO Omega-3 Fatty Acids</title>
          <description>ACTIVE Vitamin D = Vitamin D3, one 2000 IU capsule/day; PLACEBO Omega-3 Fatty Acids, one capsule/day</description>
        </group>
        <group group_id="P3">
          <title>PLACEBO Vitamin D + ACTIVE Omega-3 Fatty Acids</title>
          <description>PLACEBO Vitamin D, one capsule/day; ACTIVE Omega-3 Fatty Acids = Omacor, one 1-gram capsule/day. Each capsule of Omacor contains 840 milligrams of marine omega-3 fatty acids (465 mg of eicosapentaenoic acid [EPA] and 375 mg of docosahexaenoic acid [DHA]).</description>
        </group>
        <group group_id="P4">
          <title>PLACEBO Vitamin D + PLACEBO Omega-3 Fatty Acids</title>
          <description>PLACEBO Vitamin D, one capsule/day; PLACEBO Omega-3 Fatty Acids, one capsule/day</description>
        </group>
      </group_list>
      <period_list>
        <period>
          <title>Overall Study</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="6463"/>
                <participants group_id="P2" count="6464"/>
                <participants group_id="P3" count="6470"/>
                <participants group_id="P4" count="6474"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>Knee Pain Cohort Within VITAL Trial</title>
              <participants_list>
                <participants group_id="P1" count="342"/>
                <participants group_id="P2" count="332"/>
                <participants group_id="P3" count="353"/>
                <participants group_id="P4" count="371"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>Biomarkers of Systemic Inflammation Cohort Within VITAL Trial</title>
              <participants_list>
                <participants group_id="P1" count="392"/>
                <participants group_id="P2" count="392"/>
                <participants group_id="P3" count="392"/>
                <participants group_id="P4" count="385"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="6463"/>
                <participants group_id="P2" count="6464"/>
                <participants group_id="P3" count="6470"/>
                <participants group_id="P4" count="6474"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="0"/>
                <participants group_id="P3" count="0"/>
                <participants group_id="P4" count="0"/>
              </participants_list>
            </milestone>
          </milestone_list>
        </period>
      </period_list>
    </participant_flow>

    <baseline>
      <population>Two subcohorts drawn from VITAL Trial (n = 25871). Systemic inflammation cohort included 1561 trial participants with sufficient blood sample for assays at baseline and 1year follow up, balanced by sex, matched blood draw season. Knee pain cohort included 1398 participants who reported frequent/chronic knee pain prior to enrollment + dx of knee OA.</population>
      <group_list>
        <group group_id="B1">
          <title>ACTIVE Vitamin D + ACTIVE Omega-3 Fatty Acids</title>
          <description>ACTIVE Vitamin D = Vitamin D3, one 2000 IU capsule/day; ACTIVE Omega-3 Fatty Acids = Omacor, one 1-gram capsule/day. Each capsule of Omacor contains 840 milligrams of marine omega-3 fatty acids (465 mg of eicosapentaenoic acid [EPA] and 375 mg of docosahexaenoic acid [DHA]).</description>
        </group>
        <group group_id="B2">
          <title>ACTIVE Vitamin D + PLACEBO Omega-3 Fatty Acids</title>
          <description>ACTIVE Vitamin D = Vitamin D3, one 2000 IU capsule/day; PLACEBO Omega-3 Fatty Acids, one capsule/day</description>
        </group>
        <group group_id="B3">
          <title>PLACEBO Vitamin D + ACTIVE Omega-3 Fatty Acids</title>
          <description>PLACEBO Vitamin D, one capsule/day; ACTIVE Omega-3 Fatty Acids = Omacor, one 1-gram capsule/day. Each capsule of Omacor contains 840 milligrams of marine omega-3 fatty acids (465 mg of eicosapentaenoic acid [EPA] and 375 mg of docosahexaenoic acid [DHA]).</description>
        </group>
        <group group_id="B4">
          <title>PLACEBO Vitamin D + PLACEBO Omega-3 Fatty Acids</title>
          <description>PLACEBO Vitamin D, one capsule/day; PLACEBO Omega-3 Fatty Acids, one capsule/day</description>
        </group>
        <group group_id="B5">
          <title>Total</title>
          <description>Total of all reporting groups</description>
        </group>
      </group_list>
      <analyzed_list>
        <analyzed>
          <units>Participants</units>
          <scope>Overall</scope>
          <count_list>
            <count group_id="B1" value="6463"/>
            <count group_id="B2" value="6464"/>
            <count group_id="B3" value="6470"/>
            <count group_id="B4" value="6474"/>
            <count group_id="B5" value="25871"/>
          </count_list>
        </analyzed>
      </analyzed_list>
      <measure_list>
        <measure>
          <title>Age</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>&lt;=18 years</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                    <measurement group_id="B4" value="0"/>
                    <measurement group_id="B5" value="0"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Between 18 and 65 years</title>
                  <measurement_list>
                    <measurement group_id="B1" value="2458"/>
                    <measurement group_id="B2" value="2462"/>
                    <measurement group_id="B3" value="2461"/>
                    <measurement group_id="B4" value="2467"/>
                    <measurement group_id="B5" value="9848"/>
                  </measurement_list>
                </category>
                <category>
                  <title>&gt;=65 years</title>
                  <measurement_list>
                    <measurement group_id="B1" value="4005"/>
                    <measurement group_id="B2" value="4002"/>
                    <measurement group_id="B3" value="4009"/>
                    <measurement group_id="B4" value="4007"/>
                    <measurement group_id="B5" value="16023"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Age</title>
          <units>Years</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="67.1" spread="7.1"/>
                    <measurement group_id="B2" value="67.1" spread="7.0"/>
                    <measurement group_id="B3" value="67.2" spread="7.1"/>
                    <measurement group_id="B4" value="67.1" spread="7.1"/>
                    <measurement group_id="B5" value="67.1" spread="7.1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Sex/Gender, Customized</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <title>Female</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="3276"/>
                    <measurement group_id="B2" value="3271"/>
                    <measurement group_id="B3" value="3271"/>
                    <measurement group_id="B4" value="3267"/>
                    <measurement group_id="B5" value="13085"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Male</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="3187"/>
                    <measurement group_id="B2" value="3193"/>
                    <measurement group_id="B3" value="3199"/>
                    <measurement group_id="B4" value="3207"/>
                    <measurement group_id="B5" value="12786"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Race/Ethnicity, Customized</title>
          <population>Race/Ethnicity measured using different categories in systemic inflammation versus knee pain subcohorts.</population>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <title>Non-Hispanic white</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="4515"/>
                    <measurement group_id="B2" value="4498"/>
                    <measurement group_id="B3" value="4529"/>
                    <measurement group_id="B4" value="4504"/>
                    <measurement group_id="B5" value="18046"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>African American</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="1278"/>
                    <measurement group_id="B2" value="1275"/>
                    <measurement group_id="B3" value="1271"/>
                    <measurement group_id="B4" value="1282"/>
                    <measurement group_id="B5" value="5106"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Hispanic (not African American)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="246"/>
                    <measurement group_id="B2" value="270"/>
                    <measurement group_id="B3" value="245"/>
                    <measurement group_id="B4" value="252"/>
                    <measurement group_id="B5" value="1013"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Asian/Pacific Islander</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="102"/>
                    <measurement group_id="B2" value="86"/>
                    <measurement group_id="B3" value="98"/>
                    <measurement group_id="B4" value="102"/>
                    <measurement group_id="B5" value="388"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Native American/ Alaskan Native</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="62"/>
                    <measurement group_id="B2" value="56"/>
                    <measurement group_id="B3" value="58"/>
                    <measurement group_id="B4" value="52"/>
                    <measurement group_id="B5" value="228"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Other/ unknown</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="126"/>
                    <measurement group_id="B2" value="133"/>
                    <measurement group_id="B3" value="123"/>
                    <measurement group_id="B4" value="141"/>
                    <measurement group_id="B5" value="523"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Region of Enrollment</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>United States</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="6463"/>
                    <measurement group_id="B2" value="6464"/>
                    <measurement group_id="B3" value="6470"/>
                    <measurement group_id="B4" value="6474"/>
                    <measurement group_id="B5" value="25871"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </measure_list>
    </baseline>

    <outcome_list>
      <outcome>
        <type>Primary</type>
        <title>Serum Levels of Biomarkers of Systemic Inflammation: Interleukin-6 (IL-6)</title>
        <description>In a subsample of the randomized trial population across the four arms, blood samples at baseline and in follow-up were collected and analyzed for changes in biomarkers of systemic inflammation: C-reactive protein (CRP), interleukin-6 (IL-6), and tumor necrosis factor-receptor 2 (TNFR2). We tested whether either or both supplements were associated with a decrease in the biomarkers of systemic inflammation (blood biomarker levels among those receiving supplements vs. placebo).</description>
        <time_frame>Baseline and 1 year</time_frame>
        <population>Subsample of the VITAL trial participants at baseline and one year.</population>
        <group_list>
          <group group_id="O1">
            <title>Active Vitamin D</title>
            <description>Vitamin D3, one 2000 IU capsule/day</description>
          </group>
          <group group_id="O2">
            <title>Placebo Vitamin D</title>
            <description>Vitamin D placebo, one capsule/day</description>
          </group>
          <group group_id="O3">
            <title>Active n-3 FA</title>
            <description>Omacor, one 1-g capsule/day. Each capsule of Omacor contains 840 mg of marine omega-3 fatty acids (465 mg of EPA + 375 mg of DHA).</description>
          </group>
          <group group_id="O4">
            <title>Placebo n-3 FA</title>
            <description>Omega-3 fatty acids placebo, one capsule/day</description>
          </group>
        </group_list>
        <measure>
          <title>Serum Levels of Biomarkers of Systemic Inflammation: Interleukin-6 (IL-6)</title>
          <description>In a subsample of the randomized trial population across the four arms, blood samples at baseline and in follow-up were collected and analyzed for changes in biomarkers of systemic inflammation: C-reactive protein (CRP), interleukin-6 (IL-6), and tumor necrosis factor-receptor 2 (TNFR2). We tested whether either or both supplements were associated with a decrease in the biomarkers of systemic inflammation (blood biomarker levels among those receiving supplements vs. placebo).</description>
          <population>Subsample of the VITAL trial participants at baseline and one year.</population>
          <units>pg/ml</units>
          <param>Geometric Mean</param>
          <dispersion>95% Confidence Interval</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="784"/>
                <count group_id="O2" value="777"/>
                <count group_id="O3" value="784"/>
                <count group_id="O4" value="777"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Baseline ln (IL-6) pg/ml, geometric mean (95% Cl)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1.71" lower_limit="1.65" upper_limit="1.78"/>
                    <measurement group_id="O2" value="1.68" lower_limit="1.61" upper_limit="1.74"/>
                    <measurement group_id="O3" value="1.69" lower_limit="1.63" upper_limit="1.75"/>
                    <measurement group_id="O4" value="1.70" lower_limit="1.63" upper_limit="1.77"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Year 1 ln (IL-6) pg/mL, geometric mean (95% CI)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1.80" lower_limit="1.73" upper_limit="1.87"/>
                    <measurement group_id="O2" value="1.63" lower_limit="1.57" upper_limit="1.69"/>
                    <measurement group_id="O3" value="1.70" lower_limit="1.64" upper_limit="1.77"/>
                    <measurement group_id="O4" value="1.72" lower_limit="1.66" upper_limit="1.79"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <groups_desc>Geometric means of biomarker concentrations with 95% CIs were calculated for baseline and 1 year biomarkers (IL-6, TNFR2 and CRP) by treatment group (active vs. placebo vitamin D). Linear repeated measures models calculated the % change in means for each biomarker from baseline to year one and the overall effects of randomized treatments with 95% CIs.</groups_desc>
            <non_inferiority_type>Other</non_inferiority_type>
            <non_inferiority_desc>Test of change from baseline as above. Test for interaction on multiplicative scale between vitamin D and fish oil.</non_inferiority_desc>
            <p_value>0.02</p_value>
            <p_value_desc>1. IL-6 from baseline to one year: overall % change= 8.19% (95%CI 1.52-15.31).</p_value_desc>
            <method>as above</method>
            <method_desc>p above adjusted for age, sex, race and n-3 fatty acid randomized treatment group.&#xD;
p for interaction between vitamin D and fish oil= 0.12</method_desc>
            <param_type>Percent change in means</param_type>
            <param_value>8.19</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>1.52</ci_lower_limit>
            <ci_upper_limit>15.31</ci_upper_limit>
            <estimate_desc>p for interaction on multiplicative scale</estimate_desc>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O3</group_id>
              <group_id>O4</group_id>
            </group_id_list>
            <groups_desc>Geometric means of biomarker concentrations with 95% CIs were calculated for baseline and 1 year biomarkers (IL-6, TNFR2 and CRP) by treatment group (active vs. placebo vitamin D). Linear repeated measures models calculated the % change in means for each biomarker from baseline to year one and the overall effects of randomized treatments with 95% CIs.</groups_desc>
            <non_inferiority_type>Other</non_inferiority_type>
            <non_inferiority_desc>Test of change from baseline as above. Test for interaction on multiplicative scale between vitamin D and fish oil.</non_inferiority_desc>
            <p_value>0.97</p_value>
            <p_value_desc>4. IL-6 from baseline to one year: overall % change= -0.73% (95%CI -6.87 to 5.81).</p_value_desc>
            <method>as above</method>
            <method_desc>p above adjusted for age, sex, race and vitamin D randomized treatment group. p for interaction between fish oil and vitamin D= 0.22</method_desc>
            <param_type>Percent change in means</param_type>
            <param_value>-0.73</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-6.87</ci_lower_limit>
            <ci_upper_limit>5.81</ci_upper_limit>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Serum Levels of Biomarkers of Systemic Inflammation: C-reactive Protein (CRP)</title>
        <description>In a subsample of the randomized trial population across the four arms, blood samples at baseline and in follow-up were collected and analyzed for changes in biomarkers of systemic inflammation: C-reactive protein (CRP), interleukin-6 (IL-6), and tumor necrosis factor-receptor 2 (TNFR2). We tested whether either or both supplements were associated with a decrease in the biomarkers of systemic inflammation (blood biomarker levels among those receiving supplements vs. placebo).</description>
        <time_frame>Baseline and 1 year</time_frame>
        <population>Subsample of the VITAL trial participants at baseline and one year.</population>
        <group_list>
          <group group_id="O1">
            <title>Active Vitamin D</title>
            <description>Vitamin D3, one 2000 IU capsule/day</description>
          </group>
          <group group_id="O2">
            <title>Placebo Vitamin D</title>
            <description>Vitamin D placebo, one capsule/day</description>
          </group>
          <group group_id="O3">
            <title>Active n-3 FA</title>
            <description>Omacor, one 1-g capsule/day. Each capsule of Omacor contains 840 mg of marine omega-3 fatty acids (465 mg of EPA + 375 mg of DHA).</description>
          </group>
          <group group_id="O4">
            <title>Placebo n-3 FA</title>
            <description>Omega-3 fatty acids placebo, one capsule/day</description>
          </group>
        </group_list>
        <measure>
          <title>Serum Levels of Biomarkers of Systemic Inflammation: C-reactive Protein (CRP)</title>
          <description>In a subsample of the randomized trial population across the four arms, blood samples at baseline and in follow-up were collected and analyzed for changes in biomarkers of systemic inflammation: C-reactive protein (CRP), interleukin-6 (IL-6), and tumor necrosis factor-receptor 2 (TNFR2). We tested whether either or both supplements were associated with a decrease in the biomarkers of systemic inflammation (blood biomarker levels among those receiving supplements vs. placebo).</description>
          <population>Subsample of the VITAL trial participants at baseline and one year.</population>
          <units>mg/L</units>
          <param>Geometric Mean</param>
          <dispersion>95% Confidence Interval</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="784"/>
                <count group_id="O2" value="777"/>
                <count group_id="O3" value="784"/>
                <count group_id="O4" value="777"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Baseline ln (hsCRP) mg/L, geometric mean (95% Cl)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1.48" lower_limit="1.40" upper_limit="1.57"/>
                    <measurement group_id="O2" value="1.51" lower_limit="1.43" upper_limit="1.60"/>
                    <measurement group_id="O3" value="1.57" lower_limit="1.49" upper_limit="1.66"/>
                    <measurement group_id="O4" value="1.43" lower_limit="1.35" upper_limit="1.51"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Year 1 ln (hsCRP) mg/L, geometric mean (95% CI)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1.62" lower_limit="1.53" upper_limit="1.71"/>
                    <measurement group_id="O2" value="1.54" lower_limit="1.46" upper_limit="1.63"/>
                    <measurement group_id="O3" value="1.63" lower_limit="1.54" upper_limit="1.72"/>
                    <measurement group_id="O4" value="1.53" lower_limit="1.45" upper_limit="1.62"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <groups_desc>Geometric means of biomarker concentrations with 95% CIs were calculated for baseline and 1 year biomarkers (IL-6, TNFR2 and CRP) by treatment group (active vs. placebo vitamin D). Linear repeated measures models calculated the % change in means for each biomarker from baseline to year one and the overall effects of randomized treatments with 95% CIs.</groups_desc>
            <non_inferiority_type>Other</non_inferiority_type>
            <non_inferiority_desc>Test of change from baseline as above. Test for interaction on multiplicative scale between vitamin D and fish oil.</non_inferiority_desc>
            <p_value>0.16</p_value>
            <p_value_desc>3. HsCRP from baseline to one year: overall % change= 7.12% (95%CI -1.81-16.78).</p_value_desc>
            <method>as above</method>
            <method_desc>p above adjusted for age, sex, race and n-3 fatty acid randomized treatment group.&#xD;
p for interaction between vitamin D and fish oil= 0.38</method_desc>
            <param_type>Percent change in means</param_type>
            <param_value>7.12</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-1.81</ci_lower_limit>
            <ci_upper_limit>16.87</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O3</group_id>
              <group_id>O4</group_id>
            </group_id_list>
            <groups_desc>Geometric means of biomarker concentrations with 95% CIs were calculated for baseline and 1 year biomarkers (IL-6, TNFR2 and CRP) by treatment group (active vs. placebo vitamin D). Linear repeated measures models calculated the % change in means for each biomarker from baseline to year one and the overall effects of randomized treatments with 95% CIs.</groups_desc>
            <non_inferiority_type>Other</non_inferiority_type>
            <non_inferiority_desc>Test of change from baseline as above. Test for interaction on multiplicative scale between vitamin D and fish oil.</non_inferiority_desc>
            <p_value>0.44</p_value>
            <p_value_desc>6. HsCRP from baseline to one year: overall % change= -3.89% (95%CI -11.92-4.86).</p_value_desc>
            <method>as above</method>
            <method_desc>p above adjusted for age, sex, race and vitamin D randomized treatment group. p for interaction between fish oil and vitamin D= 0.38</method_desc>
            <param_type>Percent change in means</param_type>
            <param_value>-3.89</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-11.92</ci_lower_limit>
            <ci_upper_limit>4.86</ci_upper_limit>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Serum Levels of Biomarkers of Systemic Inflammation: Tumor Necrosis Factor-receptor 2 (TNFR2)</title>
        <description>In a subsample of the randomized trial population across the four arms, blood samples at baseline and in follow-up were collected and analyzed for changes in biomarkers of systemic inflammation: C-reactive protein (CRP), interleukin-6 (IL-6), and tumor necrosis factor-receptor 2 (TNFR2). We tested whether either or both supplements were associated with a decrease in the biomarkers of systemic inflammation (blood biomarker levels among those receiving supplements vs. placebo).</description>
        <time_frame>Baseline and 1 year</time_frame>
        <population>Subsample of the VITAL trial participants at baseline and one year.</population>
        <group_list>
          <group group_id="O1">
            <title>Active Vitamin D</title>
            <description>Vitamin D3, one 2000 IU capsule/day</description>
          </group>
          <group group_id="O2">
            <title>Placebo Vitamin D</title>
            <description>Vitamin D placebo, one capsule/day</description>
          </group>
          <group group_id="O3">
            <title>Active n-3 FA</title>
            <description>Omacor, one 1-g capsule/day. Each capsule of Omacor contains 840 mg of marine omega-3 fatty acids (465 mg of EPA + 375 mg of DHA).</description>
          </group>
          <group group_id="O4">
            <title>Placebo n-3 FA</title>
            <description>Omega-3 fatty acids placebo, one capsule/day</description>
          </group>
        </group_list>
        <measure>
          <title>Serum Levels of Biomarkers of Systemic Inflammation: Tumor Necrosis Factor-receptor 2 (TNFR2)</title>
          <description>In a subsample of the randomized trial population across the four arms, blood samples at baseline and in follow-up were collected and analyzed for changes in biomarkers of systemic inflammation: C-reactive protein (CRP), interleukin-6 (IL-6), and tumor necrosis factor-receptor 2 (TNFR2). We tested whether either or both supplements were associated with a decrease in the biomarkers of systemic inflammation (blood biomarker levels among those receiving supplements vs. placebo).</description>
          <population>Subsample of the VITAL trial participants at baseline and one year.</population>
          <units>pg/ml</units>
          <param>Geometric Mean</param>
          <dispersion>95% Confidence Interval</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="784"/>
                <count group_id="O2" value="777"/>
                <count group_id="O3" value="784"/>
                <count group_id="O4" value="777"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Baseline ln (TNFR2) pg/ml, geometric mean (95% Cl)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="2546.5" lower_limit="2508.6" upper_limit="2584.9"/>
                    <measurement group_id="O2" value="2525.4" lower_limit="2482.7" upper_limit="2568.9"/>
                    <measurement group_id="O3" value="2571.3" lower_limit="2528.1" upper_limit="2615.2"/>
                    <measurement group_id="O4" value="2500.9" lower_limit="2463.6" upper_limit="2538.8"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Year 1 ln (TNFR2) pg/mL, geometric mean (95% CI)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="2604.7" lower_limit="2565.2" upper_limit="2644.7"/>
                    <measurement group_id="O2" value="2567.9" lower_limit="2523.9" upper_limit="2612.7"/>
                    <measurement group_id="O3" value="2605.3" lower_limit="2561.4" upper_limit="2649.9"/>
                    <measurement group_id="O4" value="2567.3" lower_limit="2527.7" upper_limit="2607.6"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <groups_desc>Geometric means of biomarker concentrations with 95% CIs were calculated for baseline and 1 year biomarkers (IL-6, TNFR2 and CRP) by treatment group (active vs. placebo vitamin D). Linear repeated measures models calculated the % change in means for each biomarker from baseline to year one and the overall effects of randomized treatments with 95% CIs.</groups_desc>
            <non_inferiority_type>Other</non_inferiority_type>
            <non_inferiority_desc>Test of change from baseline as above. Test for interaction on multiplicative scale between vitamin D and fish oil.</non_inferiority_desc>
            <p_value>0.57</p_value>
            <p_value_desc>2. TNFR2 from baseline to one year: overall % change= 0.63% (95%CI -1.03 to 2.31).</p_value_desc>
            <method>as above</method>
            <method_desc>p above adjusted for age, sex, race and n-3 fatty acid randomized treatment group.&#xD;
p for interaction between vitamin D and fish oil= 0.74</method_desc>
            <param_type>Percent change in means</param_type>
            <param_value>0.63</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-1.03</ci_lower_limit>
            <ci_upper_limit>2.31</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O3</group_id>
              <group_id>O4</group_id>
            </group_id_list>
            <groups_desc>Geometric means of biomarker concentrations with 95% CIs were calculated for baseline and 1 year biomarkers (IL-6, TNFR2 and CRP) by treatment group (active vs. placebo vitamin D). Linear repeated measures models calculated the % change in means for each biomarker from baseline to year one and the overall effects of randomized treatments with 95% CIs.</groups_desc>
            <non_inferiority_type>Other</non_inferiority_type>
            <non_inferiority_desc>Test of change from baseline as above. Test for interaction on multiplicative scale between vitamin D and fish oil.</non_inferiority_desc>
            <p_value>0.13</p_value>
            <p_value_desc>5. TNFR2 from baseline to one year: overall % change= -1.27% (95%CI -2.89 to 0.39).</p_value_desc>
            <method>as above</method>
            <method_desc>p above adjusted for age, sex, race and vitamin D randomized treatment group. p for interaction between fish oil and vitamin D= 0.74</method_desc>
            <param_type>Percent change in means</param_type>
            <param_value>-1.27</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-2.89</ci_lower_limit>
            <ci_upper_limit>0.39</ci_upper_limit>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Incident Autoimmune Diseases</title>
        <description>All participants will be followed for the development of new autoimmune diseases, including, but not limited to, rheumatoid arthritis, psoriasis, autoimmune thyroid disease, inflammatory bowel disease and polymyalgia rheumatica.&#xD;
Data are not yet published. They are under review at journal and embargoed.</description>
        <time_frame>5 years (Data are not yet published. They are under review at journal and embargoed.)</time_frame>
        <posting_date>12/2022</posting_date>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Interactions Between the Effects of Vitamin D and Those of Fish Oils for Each of the Primary Outcomes. Reported With Main Results.</title>
        <description>We will test for interactions between the effects of vitamin D and those of fish oils for each of the primary outcomes above: (A) whether either or both supplements are associated with reduced numbers of new cases of autoimmune diseases; (B) whether either or both supplements are associated with reductions in biomarkers of systemic inflammation and; (C) whether either or both supplements are associated with reduced levels of knee pain at the end of the trial.&#xD;
Data are not yet published. They are under review at journal and embargoed.</description>
        <time_frame>5 years (Data are not yet published. They are under review at journal and embargoed.)</time_frame>
        <posting_date>12/2022</posting_date>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Subgroup Analysis of Primary Outcomes. Reported With Main Results, Primary Outcomes.</title>
        <description>We will test for differential effects of and interactions between vitamin D and fish oils for each of the three primary outcomes, according to participant age, race, sex and BMI. We will test for these interactions for each of the primary aims above: (A) whether either or both supplements are associated with reduced numbers of new cases of autoimmune diseases; (B) whether either or both supplements are associated with reductions in biomarkers of systemic inflammation and; (C) whether either or both supplements are associated with reduced levels of knee pain at the end of the trial.&#xD;
Data are not yet published. They are under review at journal and embargoed.</description>
        <time_frame>5 years (Data are not yet published. They are under review at journal and embargoed.)</time_frame>
        <posting_date>12/2022</posting_date>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Incident Autoimmune Disease</title>
        <description>Development of new autoimmune diseases through open-label extension beyond the randomized 5 years&#xD;
Data are not yet published. They are under review at journal and embargoed.</description>
        <time_frame>8 years (Data are not yet published. They are under review at journal and embargoed.)</time_frame>
        <posting_date>12/2022</posting_date>
      </outcome>
      <outcome>
        <type>Other Pre-specified</type>
        <title>Severity of Knee Pain in Subsample With Chronic, Frequent Knee Pain at Baseline- With n-3 FA</title>
        <description>Western Ontario and McMaster University Osteoarthritis Index (WOMAC) Pain was the primary outcome on a scale of 0-100 with 100= worst pain.&#xD;
Subsample of VITAL participants with chronic, frequent knee pain at trial baseline were followed with annual WOMAC questionnaires to test for change in severity of chronic knee pain in those taking Omega-3 fish oil (n-3 FA) supplements compared to those taking placebo. We tested whether n-3 FA supplements are associated with reduced levels of WOMAC knee pain at the end of the trial (comparing knee pain outcomes in those receiving supplements to placebo).</description>
        <time_frame>Baseline and 5 years</time_frame>
        <population>Subsample of the VITAL trial who reported chronic frequent knee pain prior to randomization.</population>
        <group_list>
          <group group_id="O1">
            <title>Active n-3 FA</title>
            <description>Omacor, one 1-g capsule/day. Each capsule of Omacor contains 840 mg of marine omega-3 fatty acids (465 mg of EPA + 375 mg of DHA) + Vitamin D3, one 2000 IU capsule/day or Vitamin D placebo, one capsule/day</description>
          </group>
          <group group_id="O2">
            <title>Placebo n-3 FA</title>
            <description>Omega-3 fatty acids placebo, one capsule/day + Vitamin D3, one 2000 IU capsule/day or Vitamin D placebo, one capsule/day</description>
          </group>
        </group_list>
        <measure>
          <title>Severity of Knee Pain in Subsample With Chronic, Frequent Knee Pain at Baseline- With n-3 FA</title>
          <description>Western Ontario and McMaster University Osteoarthritis Index (WOMAC) Pain was the primary outcome on a scale of 0-100 with 100= worst pain.&#xD;
Subsample of VITAL participants with chronic, frequent knee pain at trial baseline were followed with annual WOMAC questionnaires to test for change in severity of chronic knee pain in those taking Omega-3 fish oil (n-3 FA) supplements compared to those taking placebo. We tested whether n-3 FA supplements are associated with reduced levels of WOMAC knee pain at the end of the trial (comparing knee pain outcomes in those receiving supplements to placebo).</description>
          <population>Subsample of the VITAL trial who reported chronic frequent knee pain prior to randomization.</population>
          <units>WOMAC units on a scale</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="595"/>
                <count group_id="O2" value="626"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Baseline mean WOMAC Pain</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="36.5" spread="0.7"/>
                    <measurement group_id="O2" value="35.4" spread="0.7"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Follow Up mean WOMAC pain</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="33.6" spread="0.9"/>
                    <measurement group_id="O2" value="33.7" spread="0.9"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <groups_desc>Intention to treat analysis using a repeated measures model with unstructured variance to assess the effect of treatment arm on WOMAC Pain adjusting for age, sex, and the other treatment arm. The linear time by treatment interaction term assessed change in WOMAC Pain over time between participants randomized to treatment versus placebo.</groups_desc>
            <non_inferiority_type>Other</non_inferiority_type>
            <non_inferiority_desc>We assessed the main effects of the treatment arms comparing all those randomized to omega-3 fatty acids or omega-3 fatty acid placebo, regardless of vitamin D randomization status.</non_inferiority_desc>
            <p_value>0.77</p_value>
            <p_value_desc>Repeated measures model with unstructured variance to assess effect of treatment on WOMAC Pain adjusting for age, sex, and other treatment. Linear time by treatment interaction term assessed change in WOMAC Pain over time in treatment vs placebo.</p_value_desc>
            <method>Mixed Models Analysis</method>
            <method_desc>Repeated measures model with censoring for total knee replacement.</method_desc>
            <other_analysis_desc>We assessed for effect modification between n-3 FA and vitamin D and tested for other pre-specified interactions. We again used a repeated measures model with censoring for TKR. We adjusted for age, sex and vitamin D treatment arm (in analyses in which vitamin D treatment arm was not investigated as a potential modifier).</other_analysis_desc>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Other Pre-specified</type>
        <title>Severity of Knee Pain in Subsample With Chronic, Frequent Knee Pain at Baseline- With Vitamin D</title>
        <description>Western Ontario and McMaster University Osteoarthritis Index (WOMAC) Pain was the primary outcome on a scale of 0-100 with 100= worst pain.&#xD;
Subsample of VITAL participants with chronic, frequent knee pain at trial baseline were followed with annual WOMAC questionnaires to test for change in severity of chronic knee pain in those taking Vitamin D supplements compared to those taking placebo. We tested whether Vitamin D supplements were associated with reduced levels of WOMAC knee pain at the end of the trial (comparing knee pain outcomes in those receiving supplements to placebo).</description>
        <time_frame>Baseline and 5 years</time_frame>
        <population>Subsample of VITAL trial participants with chronic, frequent knee pain at baseline prior to randomization.</population>
        <group_list>
          <group group_id="O1">
            <title>Active Vitamin D</title>
            <description>Vitamin D3, one 2000 IU capsule/day + Omega 3 Omacor fatty acid, 1-g capsule/day or Omega-3 fatty acid placebo</description>
          </group>
          <group group_id="O2">
            <title>Placebo Vitamin D</title>
            <description>Placebo vitamin D3, one 2000 IU capsule/day + Omega 3 Omacor fatty acid, 1-g capsule/day or Omega-3 fatty acid placebo</description>
          </group>
        </group_list>
        <measure>
          <title>Severity of Knee Pain in Subsample With Chronic, Frequent Knee Pain at Baseline- With Vitamin D</title>
          <description>Western Ontario and McMaster University Osteoarthritis Index (WOMAC) Pain was the primary outcome on a scale of 0-100 with 100= worst pain.&#xD;
Subsample of VITAL participants with chronic, frequent knee pain at trial baseline were followed with annual WOMAC questionnaires to test for change in severity of chronic knee pain in those taking Vitamin D supplements compared to those taking placebo. We tested whether Vitamin D supplements were associated with reduced levels of WOMAC knee pain at the end of the trial (comparing knee pain outcomes in those receiving supplements to placebo).</description>
          <population>Subsample of VITAL trial participants with chronic, frequent knee pain at baseline prior to randomization.</population>
          <units>WOMAC Pain units on a scale</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="591"/>
                <count group_id="O2" value="630"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Baseline mean WOMAC Pain</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="35.4" spread="0.7"/>
                    <measurement group_id="O2" value="36.5" spread="0.7"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Follow Up mean WOMAC Pain</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="32.7" spread="0.9"/>
                    <measurement group_id="O2" value="34.6" spread="0.9"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <groups_desc>Intention to treat analysis using a repeated measures model with unstructured variance to assess the effect of treatment arm on WOMAC Pain adjusting for age, sex, and the other treatment arm. The linear time by treatment interaction term assessed change in WOMAC Pain over time between participants randomized to treatment versus placebo.</groups_desc>
            <non_inferiority_type>Other</non_inferiority_type>
            <non_inferiority_desc>We assessed the main effects of the treatment arms comparing all those randomized to vitamin D or vitamin D placebo, regardless of omega-3 fatty acid randomization status.</non_inferiority_desc>
            <p_value>0.41</p_value>
            <p_value_desc>Repeated measures model with unstructured variance to assess effect of treatment on WOMAC Pain adjusting for age, sex, and other treatment. Linear time by treatment interaction term assessed change in WOMAC Pain over time in treatment vs placebo.</p_value_desc>
            <method>Mixed Models Analysis</method>
            <method_desc>Linear time by treatment interaction (comparing change in WOMAC pain over time in two randomized groups)</method_desc>
            <other_analysis_desc>We assessed for effect modification between vitamin D and N-3 FA and tested for other pre-specified interactions. We again used a repeated measures model with censoring for TKR. We adjusted for age, sex and N-3 FA treatment arm (in analyses in which N-3 FA treatment arm was not investigated as a potential modifier).</other_analysis_desc>
          </analysis>
        </analysis_list>
      </outcome>
    </outcome_list>

    <reported_events>
      <time_frame>5 years</time_frame>
      <desc>Vit D Monitored safety cond'ns: hypercalcemia, kidney stones, parathyroid disease, kidney failure or dialysis; Other symptoms, side effects: GI bleeding, easy bruising; stomach upset or pain; nausea; constipation, diarrhea, skin rash&#xD;
Omega-3 FA Monitored safety cond'ns: GI bleeding; blood in urine; easy bruising; freq nosebleeds; kidney failure or dialysis; Other symptoms, side effects: stomach upset or pain; nausea; constipation; diarrhea; skin rash; bad taste in mouth; increased burping</desc>
      <group_list>
        <group group_id="E1">
          <title>Active Vitamin D</title>
          <description>Vitamin D3, one 2000 IU capsule/day</description>
        </group>
        <group group_id="E2">
          <title>Placebo Vitamin D</title>
          <description>Vitamin D placebo, one capsule/day</description>
        </group>
        <group group_id="E3">
          <title>Active Omega-3 Fatty Acids</title>
          <description>Omacor, one 1-g capsule/day. Each capsule of Omacor contains 840 mg of marine omega-3 fatty acids (465 mg of EPA + 375 mg of DHA).</description>
        </group>
        <group group_id="E4">
          <title>Omega-3 Fatty Acids Placebo</title>
          <description>Omega-3 fatty acids placebo, one capsule/day</description>
        </group>
      </group_list>
      <serious_events>
        <default_assessment>Systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, all-cause mortality</sub_title>
                <counts group_id="E1" subjects_affected="485" subjects_at_risk="12927"/>
                <counts group_id="E2" subjects_affected="493" subjects_at_risk="12944"/>
                <counts group_id="E3" subjects_affected="493" subjects_at_risk="12933"/>
                <counts group_id="E4" subjects_affected="485" subjects_at_risk="12938"/>
              </event>
              <event>
                <sub_title>Total, serious adverse events</sub_title>
                <counts group_id="E1" subjects_affected="1673" subjects_at_risk="12927"/>
                <counts group_id="E2" subjects_affected="1659" subjects_at_risk="12944"/>
                <counts group_id="E3" subjects_affected="1613" subjects_at_risk="12933"/>
                <counts group_id="E4" subjects_affected="1619" subjects_at_risk="12938"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Blood and lymphatic system disorders</title>
            <event_list>
              <event>
                <sub_title>Gastrointestinal bleeding</sub_title>
                <counts group_id="E1" subjects_affected="341" subjects_at_risk="12927"/>
                <counts group_id="E2" subjects_affected="403" subjects_at_risk="12944"/>
                <counts group_id="E3" subjects_affected="370" subjects_at_risk="12933"/>
                <counts group_id="E4" subjects_affected="374" subjects_at_risk="12938"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Endocrine disorders</title>
            <event_list>
              <event>
                <sub_title>Hypercalcemia</sub_title>
                <counts group_id="E1" subjects_affected="147" subjects_at_risk="12927"/>
                <counts group_id="E2" subjects_affected="143" subjects_at_risk="12944"/>
                <counts group_id="E3" subjects_affected="151" subjects_at_risk="12933"/>
                <counts group_id="E4" subjects_affected="139" subjects_at_risk="12938"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Neoplasms benign, malignant and unspecified (incl cysts and polyps)</title>
            <event_list>
              <event>
                <sub_title>Invasive cancer of any type</sub_title>
                <description>Total cancer = invasive cancer of any type</description>
                <counts group_id="E1" subjects_affected="793" subjects_at_risk="12927"/>
                <counts group_id="E2" subjects_affected="824" subjects_at_risk="12944"/>
                <counts group_id="E3" subjects_affected="820" subjects_at_risk="12933"/>
                <counts group_id="E4" subjects_affected="797" subjects_at_risk="12938"/>
              </event>
              <event>
                <sub_title>Death from cancer</sub_title>
                <counts group_id="E1" subjects_affected="154" subjects_at_risk="12927"/>
                <counts group_id="E2" subjects_affected="187" subjects_at_risk="12944"/>
                <counts group_id="E3" subjects_affected="168" subjects_at_risk="12933"/>
                <counts group_id="E4" subjects_affected="173" subjects_at_risk="12938"/>
              </event>
              <event>
                <sub_title>Breast cancer (in women)</sub_title>
                <counts group_id="E1" subjects_affected="124" subjects_at_risk="12927"/>
                <counts group_id="E2" subjects_affected="122" subjects_at_risk="12944"/>
                <counts group_id="E3" subjects_affected="117" subjects_at_risk="12933"/>
                <counts group_id="E4" subjects_affected="129" subjects_at_risk="12938"/>
              </event>
              <event>
                <sub_title>Prostate cancer (in men)</sub_title>
                <counts group_id="E1" subjects_affected="192" subjects_at_risk="12927"/>
                <counts group_id="E2" subjects_affected="219" subjects_at_risk="12944"/>
                <counts group_id="E3" subjects_affected="219" subjects_at_risk="12933"/>
                <counts group_id="E4" subjects_affected="192" subjects_at_risk="12938"/>
              </event>
              <event>
                <sub_title>Colorectal cancer</sub_title>
                <counts group_id="E1" subjects_affected="51" subjects_at_risk="12927"/>
                <counts group_id="E2" subjects_affected="47" subjects_at_risk="12944"/>
                <counts group_id="E3" subjects_affected="54" subjects_at_risk="12933"/>
                <counts group_id="E4" subjects_affected="44" subjects_at_risk="12938"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Vascular disorders</title>
            <event_list>
              <event>
                <sub_title>Major cardiovascular event</sub_title>
                <description>Major cardiovascular event = a composite endpoint of myocardial infarction, stroke, and death from cardiovascular causes</description>
                <counts group_id="E1" subjects_affected="396" subjects_at_risk="12927"/>
                <counts group_id="E2" subjects_affected="409" subjects_at_risk="12944"/>
                <counts group_id="E3" subjects_affected="386" subjects_at_risk="12933"/>
                <counts group_id="E4" subjects_affected="419" subjects_at_risk="12938"/>
              </event>
              <event>
                <sub_title>Myocardial infarction</sub_title>
                <counts group_id="E1" subjects_affected="169" subjects_at_risk="12927"/>
                <counts group_id="E2" subjects_affected="176" subjects_at_risk="12944"/>
                <counts group_id="E3" subjects_affected="145" subjects_at_risk="12933"/>
                <counts group_id="E4" subjects_affected="200" subjects_at_risk="12938"/>
              </event>
              <event>
                <sub_title>Stroke</sub_title>
                <counts group_id="E1" subjects_affected="141" subjects_at_risk="12927"/>
                <counts group_id="E2" subjects_affected="149" subjects_at_risk="12944"/>
                <counts group_id="E3" subjects_affected="148" subjects_at_risk="12933"/>
                <counts group_id="E4" subjects_affected="142" subjects_at_risk="12938"/>
              </event>
              <event>
                <sub_title>Death from cardiovascular causes</sub_title>
                <counts group_id="E1" subjects_affected="152" subjects_at_risk="12927"/>
                <counts group_id="E2" subjects_affected="138" subjects_at_risk="12944"/>
                <counts group_id="E3" subjects_affected="142" subjects_at_risk="12933"/>
                <counts group_id="E4" subjects_affected="148" subjects_at_risk="12938"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </serious_events>
      <other_events>
        <frequency_threshold>0</frequency_threshold>
        <default_assessment>Systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, other adverse events</sub_title>
                <counts group_id="E1" subjects_affected="10086" subjects_at_risk="12927"/>
                <counts group_id="E2" subjects_affected="10098" subjects_at_risk="12944"/>
                <counts group_id="E3" subjects_affected="10094" subjects_at_risk="12933"/>
                <counts group_id="E4" subjects_affected="10090" subjects_at_risk="12938"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Blood and lymphatic system disorders</title>
            <event_list>
              <event>
                <sub_title>Easy bruising</sub_title>
                <counts group_id="E1" subjects_affected="3434" subjects_at_risk="12927"/>
                <counts group_id="E2" subjects_affected="3408" subjects_at_risk="12944"/>
                <counts group_id="E3" subjects_affected="3443" subjects_at_risk="12933"/>
                <counts group_id="E4" subjects_affected="3399" subjects_at_risk="12938"/>
              </event>
              <event>
                <sub_title>Frequent nosebleeds</sub_title>
                <counts group_id="E1" subjects_affected="466" subjects_at_risk="12927"/>
                <counts group_id="E2" subjects_affected="490" subjects_at_risk="12944"/>
                <counts group_id="E3" subjects_affected="465" subjects_at_risk="12933"/>
                <counts group_id="E4" subjects_affected="491" subjects_at_risk="12938"/>
              </event>
              <event>
                <sub_title>Blood in urine</sub_title>
                <counts group_id="E1" subjects_affected="911" subjects_at_risk="12927"/>
                <counts group_id="E2" subjects_affected="882" subjects_at_risk="12944"/>
                <counts group_id="E3" subjects_affected="919" subjects_at_risk="12933"/>
                <counts group_id="E4" subjects_affected="874" subjects_at_risk="12938"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Endocrine disorders</title>
            <event_list>
              <event>
                <sub_title>Parathyroid condition</sub_title>
                <description>Parathyroid condition = hyperparathyroidism or hypoparathyroidism</description>
                <counts group_id="E1" subjects_affected="50" subjects_at_risk="12927"/>
                <counts group_id="E2" subjects_affected="62" subjects_at_risk="12944"/>
                <counts group_id="E3" subjects_affected="52" subjects_at_risk="12933"/>
                <counts group_id="E4" subjects_affected="60" subjects_at_risk="12938"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Gastrointestinal disorders</title>
            <event_list>
              <event>
                <sub_title>Stomach upset or pain</sub_title>
                <counts group_id="E1" subjects_affected="4860" subjects_at_risk="12927"/>
                <counts group_id="E2" subjects_affected="4870" subjects_at_risk="12944"/>
                <counts group_id="E3" subjects_affected="4887" subjects_at_risk="12933"/>
                <counts group_id="E4" subjects_affected="4843" subjects_at_risk="12938"/>
              </event>
              <event>
                <sub_title>Nausea</sub_title>
                <counts group_id="E1" subjects_affected="3519" subjects_at_risk="12927"/>
                <counts group_id="E2" subjects_affected="3589" subjects_at_risk="12944"/>
                <counts group_id="E3" subjects_affected="3558" subjects_at_risk="12933"/>
                <counts group_id="E4" subjects_affected="3550" subjects_at_risk="12938"/>
              </event>
              <event>
                <sub_title>Constipation</sub_title>
                <counts group_id="E1" subjects_affected="5133" subjects_at_risk="12927"/>
                <counts group_id="E2" subjects_affected="5162" subjects_at_risk="12944"/>
                <counts group_id="E3" subjects_affected="5184" subjects_at_risk="12933"/>
                <counts group_id="E4" subjects_affected="5111" subjects_at_risk="12938"/>
              </event>
              <event>
                <sub_title>Diarrhea</sub_title>
                <counts group_id="E1" subjects_affected="5511" subjects_at_risk="12927"/>
                <counts group_id="E2" subjects_affected="5668" subjects_at_risk="12944"/>
                <counts group_id="E3" subjects_affected="5599" subjects_at_risk="12933"/>
                <counts group_id="E4" subjects_affected="5580" subjects_at_risk="12938"/>
              </event>
              <event>
                <sub_title>Increased burping</sub_title>
                <counts group_id="E1" subjects_affected="2168" subjects_at_risk="12927"/>
                <counts group_id="E2" subjects_affected="2207" subjects_at_risk="12944"/>
                <counts group_id="E3" subjects_affected="2217" subjects_at_risk="12933"/>
                <counts group_id="E4" subjects_affected="2158" subjects_at_risk="12938"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>General disorders</title>
            <event_list>
              <event>
                <sub_title>Bad taste in mouth</sub_title>
                <counts group_id="E1" subjects_affected="2195" subjects_at_risk="12927"/>
                <counts group_id="E2" subjects_affected="2290" subjects_at_risk="12944"/>
                <counts group_id="E3" subjects_affected="2240" subjects_at_risk="12933"/>
                <counts group_id="E4" subjects_affected="2245" subjects_at_risk="12938"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Renal and urinary disorders</title>
            <event_list>
              <event>
                <sub_title>Kidney stones</sub_title>
                <counts group_id="E1" subjects_affected="477" subjects_at_risk="12927"/>
                <counts group_id="E2" subjects_affected="426" subjects_at_risk="12944"/>
                <counts group_id="E3" subjects_affected="430" subjects_at_risk="12933"/>
                <counts group_id="E4" subjects_affected="473" subjects_at_risk="12938"/>
              </event>
              <event>
                <sub_title>Kidney failure or dialysis</sub_title>
                <counts group_id="E1" subjects_affected="85" subjects_at_risk="12927"/>
                <counts group_id="E2" subjects_affected="88" subjects_at_risk="12944"/>
                <counts group_id="E3" subjects_affected="85" subjects_at_risk="12933"/>
                <counts group_id="E4" subjects_affected="88" subjects_at_risk="12938"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Skin and subcutaneous tissue disorders</title>
            <event_list>
              <event>
                <sub_title>Skin rash</sub_title>
                <counts group_id="E1" subjects_affected="3268" subjects_at_risk="12927"/>
                <counts group_id="E2" subjects_affected="3430" subjects_at_risk="12944"/>
                <counts group_id="E3" subjects_affected="3331" subjects_at_risk="12933"/>
                <counts group_id="E4" subjects_affected="3367" subjects_at_risk="12938"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </other_events>
    </reported_events>

    <certain_agreements>
      <pi_employee>Principal Investigators are NOT employed by the organization sponsoring the study.</pi_employee>
      <restrictive_agreement>There is NOT an agreement between Principal Investigators and the Sponsor (or its agents) that restricts the PI's rights to discuss or publish trial results after the trial is completed. </restrictive_agreement>
    </certain_agreements>
    <point_of_contact>
      <name_or_title>Karen Costenbader</name_or_title>
      <organization>Brigham and Women's Hospital/ Harvard Medical School</organization>
      <phone>16177326088</phone>
      <email>kcostenbader@bwh.harvard.edu</email>
    </point_of_contact>
  </clinical_results>
</clinical_study>

